Description: Codexis, Inc. engages in the production of custom industrial enzymes for use in the pharmaceutical, biofuel, and chemical production. The company offers Codex Biocatalyst Panels and Kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. It also provides enzyme screening, enzyme optimization, and enzyme services, as well as supplies intermediates and active pharmaceutical ingredients to pharmaceutical companies. In addition, the company develops CodeXyme cellulase enzymes to convert cellulosic biomass, a non-food plant material into affordable sugars, which could then be converted into renewable fuels and chemicals; and CodeXol detergent alcohols used to manufacture surfactants, which are used as cleaning ingredients in consumer products, such as shampoos, liquid soaps, and laundry detergents. It intends to market CodeXyme cellulase enzymes to chemicals manufacturers; and CodeXol detergent alcohols as a drop-in substitute for the detergent alcohols market. The company has collaboration with Purolite Corporation to develop and market enzymes for the pharmaceutical industry. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Home Page: www.codexis.com
CDXS Technical Analysis
200 Penobscot Drive
Redwood City,
CA
94063
United States
Phone:
650 421 8100
Officers
Name | Title |
---|---|
Dr. Stephen George Dilly MBBS, Ph.D. | Pres, CEO & Director |
Mr. Ross Taylor Jr., M.B.A. | Sr. VP & CFO |
Mr. John J. Nicols | Director & Strategic Advisor |
Mr. Kevin Norrett M.B.A., M.S. | Chief Operating Officer |
Ms. Margaret Fitzgerald J.D. | Chief Legal and Compliance Officer, Gen. Counsel & Sec. |
Ms. Asli Aras Ph.D. | VP & Head of Corp. Devel. |
Ms. Karen Frechou-Armijo | Sr. VP & Head of HR |
Mr. Rob Wilson Ph.D. | Sr. VP & GM of Performance Enzymes |
Dr. Karl A. Schoene Ph.D. | Sr. VP of Devel. & Operations |
Dr. Stefan Lutz Ph.D. | Sr. VP of Research |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Life Sciences Tools & Services |
GIC Sub-Industry: | Life Sciences Tools & Services |
Forward PE: | 138.8889 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 2.3781 |
Price-to-Sales TTM: | 2.7321 |
IPO Date: | 2010-04-22 |
Fiscal Year End: | December |
Full Time Employees: | 261 |